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ABSTRACT
Protein misfolding is inevitable, 30% of newly synthesized polypeptides can end up
misfolded, and such proteins are either refolded or eliminated by cellular quality control
pathways. These pathways include the ubiquitin proteosome system and autophagy. In recent
years, protein misfolding has been implicated in the pathophysiology of many diseases such
as diabetes, neurological disorders and cancer. Studies from our laboratory have shown that
choroid plexus carcinoma tumors are characterized by the formation of aggresomes at the
microtubules organizing centers (MTOC) in formalin fixed and paraffin embedded (FFPE)
tumor tissues. This was further confirmed by the development of choroid plexus carcinoma
cell line (CCHE-45) which was characterized by the constitutive formation of aggresomes at
MTOC. Aggresome formation implies presence of toxic protein over load and/or defective
autophagy.

The role of autophagic flux in the removal of aggresomes was further

investigated. CCHE-45 cells displayed an increase in both basal and induced autophagic flux.
Furthermore, microtubule-associated protein light chain 3 A- variant 1 (LC3A-V1)
expression was silenced by promoter methylation in these cells. Restoring LC3A-V1 resulted
in the elimination of the aggresomes and the recruitment of Lysosomal-Associated
Membrane Protein (LAMP2) independent from autophagosome formation. Based on these
findings we suggest that quality control autophagy in CCHE-45 is mediated by LC3A in
aggresomes clearance. We propose that perturbation in the autophagic pathway by the
absence of LC3A expression leads to a failure in aggresome degradation thus overcoming
misfolded protein overload.
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AIM OF THE STUDY

Thirty percent of newly synthesized polypeptides can end up misfolded, such proteins are
either refolded or eliminated by cellular quality control pathways which include the ubiquitin
proteosome system and autophagy. When misfolded proteins exceed the ability of cell quality
control to be eliminated they may end up in storage compartments. Aggresomes are
juxtanuclear protein aggregates which act as a storage bins for misfolded proteins. In children
Cancer hospital 57357 a new choroid plexus carcinoma cell line CCHE-45 was established.
The cells were characterized by the presence of a single cage like inclusion body at
juxtanuclear position that was positive for vimentin. These structures have been identified
previously as aggresomes. The aim of the study is to characterize the mechanisms underlying
aggresomes clearance in choroid plexus carcinoma.
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1-LITERATURE REVIEW

1.1 Tumor Biology:
Cancer is a term that encompasses a wide class of diseases, but mainly it is used to describe
disorders that are characterized by abnormal new growth or “neoplasm” formation. The
ability of a neoplasm to invade the surrounding tissues or its invasive capacity is what
governs the tendency of the tumor to be malignant and gives it the ability to further
metastasize through blood or lymphatic vessel (Bunz, 2008). Genetic analysis on both
chromosomal and DNA levels has revealed that neoplasms mainly originate from a single
cell in what is known as the monoclonal origin of cancer cells (Nowell, Rowley, & Knudson,
1998). In the late seventies, it was hypothesized that the monoclonal cancer cell has a
selective advantage which favours its selection and allow it to proliferate and overcome the
neighbouring cells (Nowell, 1976). Later studies showed that cancer cells acquire genomic
instability and accumulated changes in multiple genes which imply that more than a single
event is required for tumorigenesis (Lengauer, Kinzler, & Vogelstein, 1998). These
aberrations usually occur either spontaneously on a somatic level or hereditary through germ
line mutations. Germ line cancers represent a small percentage (around 10%) of human
cancers. Unlike somatic gene mutations, germ line cancer genes are vertically transferred in
every cell of the carrier (Bunz, 2008).
The accumulation of genetic and /or epigenetic aberrations lead to an acquisition of a number
of survival mechanisms, hence enabling the tumor to grow and metastasis and most
importantly evade apoptosis (Virani, Colacino, Kim, & Rozek, 2013). In addition to blocking
the growth suppression mechanisms mainly involving tumor suppressor genes, inducing
angiogenesis, indefinite proliferation, immortality and acquiring a strong capability for
invasion and bypassing the immune system in what is known as the hallmarks of cancer
(Hanahan & Weinberg, 2011).
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1.2 Genetic changes contributing to cancer:

On the genetic level, cancer may arise from genetic modification in either a proto-oncogene
or a tumor suppressor gene. A proto -oncogene mutation leads to expression of a protein of a
higher biochemical activity than its non-mutated counterpart, resulting in an alteration in
cancer cell growth and differentiation (Camaco, 2012). Oncogenes encode proteins that play
different roles such as transcription factors, growth factors, growth factors receptors, signal
transduction or chromatin remodelling (Croce, 2008). The RAS gene family was among the
first oncogenes discovered in cancer. The RAS family includes (H-ras, N-ras and K-ras)
(Tabin & Weinberg, 1985). High mutation frequencies in these genes were reported in
pancreatic, colorectal and lung carcinomas. Other common oncogenes includes MLL, BCL2,
C-MYC and the ERRB families (Camaco, 2012).

On the other hand, tumor suppressor genes mutation is characterized by loss of function that
leads to perturbations in the cell cycle, genetic instability and apoptosis and ultimately results
in disruption of homeostasis inside the cell. Mutation in the RB gene in retinoblastoma, the
APC gene in colorectal cancer and the TP53 gene are common examples of tumor suppressor
genes frequently mutated in cancer (Bunz, 2008).
The most intensively studied tumor suppressor gene is the TP53 which is highly mutated in
several human malignancies. TP53 was first discovered in 1979 by Levine and Crawford
(Lane & Crawford, 1979; Linzer, Maltzman, & Levine, 1979). Few years later the gene was
located on the short arm of chromosome 17 (Muleris, Salmon, Zafrani, Girodet, & Dutrillaux,
1985). TP53 mutation could be either somatic or inherited. Germ line mutations in TP53 is
inherited in families in what is known as Li Fraumeni syndrome (LFS) leading to
predisposition to bone, brain especially choroid plexus carcinoma, lung and a number of soft
tissue scarcomas (Kamihara, Rana, & Garber, 2014). Table 1 and 2 shows tumors associated
with somatic and germ line mutations in TP53.
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Table (1): Tumors associated with somatic mutation of TP53 according to IARC TP53
mutation database, R17 release. TP53 mutation prevalence by tumor site, https://www.iarc.fr/
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Table (2): Tumors associated with TP53 germ line mutations according to IARC TP53
mutation database, R17 release. TP53 mutation prevalence by tumor site. https://www.iarc.fr/

1.2.1:Tp53 function:
TP53 is a transcription factor with an estimated 3,600 genes under its regulation (Li, et al.,
2012). Stressors such as DNA damage, hypoxia, pH change or starvation stimulate a number
of TP53 upstream mediators such as ATM, ARF and ChK2. The mediators facilitate the up
regulation of p53 through the dissociation of the P53 from its negative regulators; MDM2 an
E3 ubiquitin ligase. The P53activation leads to either cell cycle arrest in G1 or G2 phase and
or apoptosis (Kamihara, Rana, & Garber, 2013).
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Figure (1): Schematic illustration of P53 pathway showing different stresses that stimulate
TP53 upstream mediators such as ATM, ARF and ChK2. The mediators facilitate
dissociation of P53 from its negative regulators, leading to different responses (Surget,
Khoury & Bourdan, 2013).

1.3 Epigenetic changes contributing to cancer:
Epigenetic changes associated with cancer are changes in gene expression pattern
independent on DNA sequence. These changes are generated by modification events in the
DNA molecule such as post translational histone modification, DNA hypo or
hypermethylation or changes in a micro RNA level (Sharma, Kelly, & Jones, 2010). With
hopes of restoring normal functions of genes, epigenetic therapy is a new promising field in
cancer treatment based on the reversibility of epigenetic mark. Currently several FDA
approved drugs are used in cancer treatment including Temozolamide, Azacitidine and
Decitabine (Ho, Turcan, & Chan, 2013; Sharma, et al., 2010).
The three main epigenetic events contributing to cancer will be discussed further.
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1 .3.1 Non coding microRNA:

Micro RNAs (miRNA) are non-coding single stranded RNA molecules approximately 22
nucleotides long (Sharma, et al., 2010). miRNA has a role in regulating posttranscriptional
gene expression. Around 1000 micro RNA have been reported so far which down regulate
the translation of around 60% of protein coding mRNA (Friedman, Farh, Burge, & Bartel,
2009). In recent years, it is becoming evident that miRNA regulate many cellular process
including development, cell proliferation and apoptosis. In addition to regulating several
cellular processes, miRNA are have been linked several diseases including cancer (Kanwal &
Gupta, 2012). A list of altered miRNA reported in human cancers include miR21 over
expression in glioblastoma, prostate and lung cancer, miR-34b/34c up regulation in colon
cancer, miR-125 up regulation in breast cancer, miR-221 and miR-222 down regulation in
hepatocellular carcinoma and miR-92b up regulation in primary brain tumors (Kanwal &
Gupta, 2012). Furthermore, miRNA expression profile is now used for cancer classification
(Lu, et al., 2005).

1.3.2 Histone modifications:
In eukaryotes, the wrapping of the DNA around the histone proteins forming the nucleosome
packs the large genome into the nucleus while still ensuring appropriate access to it for
correct gene expression. The nucleosome core have an estimated 147 base pairs wrapped
around a histone octamer formed of 2 copies of the highly conserved H2A, H2B, H3, H4
histones (Henikoff & Ahmad, 2005). Histones have flexible N-terminus known as the histone
tail, which is susceptible to a number of covalent modifications such as acetylation,
methylation, phosphorylation and ubiquitination. Such modifications either allow formation
of the transcriptionally inactive compact heterochromatin or the open active euchromatin.
trimethylation of H3K4, H3K36 and H3K79 is characteristic of euchromatin, while
methylation of H3K9, H3K27 and H4K20 is present in heterochromatin (Kanwal & Gupta,
2012). A histone code is another epigenetic modification that regulates many DNA processes
including repair, regulation of gene expression, replication, centromere and telomere
maintenance. Recent research brought to light a number of mutations in genes that affect
histones post-translational modifications such as histone deacetylases, methyltransferases,
acetyl transferases and demethylases (Chi, Allis, & Wang, 2010). Furthermore, changes in
histone pattern of covalent modification such as increased H3K4 dimethylation or H3K18
acetylation have been linked to poor prognosis in cancer (Myzak & Dashwood, 2006).
18

1.3.3 CpG island and DNA methylation:
CpG islands are short distinctively interspersed DNA sequences around 1000 base pairs (bp)
in length. They are characterized by having a rich CG base composition; this phenomenon
enables DNA methyltransferase to covalently attach a methyl group to 5th carbon atom of
cytosine ring situated next to a guanine nucleotide forming the CpG islands (Bunz, 2008;
Sharma, et al., 2010).
CpG islands are often present in transcription initiation sites and function in maintaining a
more permissive chromatin structure which allows regulation of gene expression. In the main
CpG island are non-methylated promoting genes to be freely expressed. Nevertheless,
aberrant CpG island methylation has been associated with various types of cancers. This
aberration can include different mechanisms to induce gene silencing by either inhibiting or
activating the recruitment of regulatory proteins such as transcription factors to DNA
(Kanwal & Gupta, 2012).
Hypermethylated genes in cancers include tumor suppressor genes such as Rb promoter in
retinoblastoma, MLH1 and PTEN in colorectal cancer, BRCA1 in breast cancer and ovarian
cancer and MGMT in glioblastoma (Nagarajan & Costello, 2009; Virani, et al., 2013). Other
genes include genes involved in DNA repair, cell cycle control and apoptosis (Sharma, et al.,
2010).
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Table (3): Genes with hypermethylated promoter associated with cancer (How Kit, Nielsen,
& Tost, 2012; Sharma, et al., 2010).

DNA methylation pattern is used as a biomarker for early diagnosis, prognosis and following
up patients. The methylation pattern is tested using array or sequencing based techniques.
Some promising biomarkers include CDKN2A and RASSF1A in breast cancer, CDKN2A,
MGMT, MLH1 in colorectal tumors, CDKN2A in lung cancer and GSTP1, RASSF1A, APC
in prostate cancer (How Kit, Nielsen, & Tost, 2012; Sharma, et al., 2010).
.
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1.4 Brain tumors:
Brain tumors are the most common pediatric solid tumor and the second most common
childhood malignancy after leukemia representing 22% of all malignancies up to the age of
14 and 10% of malignancies in the age group from 15 to 19 years old (Hasselblatt, et al.,
2009). The incidence rate in Egypt is 16.9 per million per year in children less than 15 years
old (El-Gaidi, 2011). Advances in surgical intervention, chemotherapy and radiotherapy
resulted in a humble survival improvement. Molecular characterization and deep
investigation of underlying genetic drivers of different pediatric brain tumor are essential to
overcome poor therapeutic outcome and dismal survival rates.
1.4.1 Classification of primary pediatric brain tumors:
Brain tumors were historically classified according to their anatomic location in the brain
into: brain stem, hemispheric, diencephalic, cerebellar and optic regions tumors (Patel & Tse,
2004). This classification system is no longer commonly used. Zulch was the first to attempt
a histology based classification in 1979. Zulch’s classification was revised several times with
the advancement of immunohistochemistry and genetic profiling (Patel & Tse, 2004).
Nevertheless, the original classification based on the anatomic location of the brain tumors is
still being used in radiological investigation. Accordingly the four main groups are:
-Infratentorial including medulloblastoma, cerebellar astrocytomas, atypical teratoid/rhabdoid
tumors and choroid plexus carcinoma.
-Supratentorial tumors including low-grade cerebral hemispheric astrocytomas, high-grade or
malignant astrocytomas, primitive neuroectodermal tumors (PNETs), ependymomas, atypical
teratoid/rhabdoid tumors and choroid plexus carcinoma.
-Parasellar tumors include craniopharyngiomas and germ cell tumors.
-Spinal cord tumors include gangliogliomas, ependymomas, low-grade cerebral hemispheric
astrocytomas and high-grade or malignant astrocytomas.
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Figure (2): Morphological patterns of brain tumors showing the most common: astrocytoma,
cerebellar astrocytoma, infratentorial ependymona, brain stem glioma, craniopharyngioma,
optic glioma and medulloblastoma, www.hopkinsmedecine.org.
Currently the most commonly used classification is the World Health Organization (WHO)
pediatric brain tumors classification which is based on the cell of origin which includes:
- Gliomas for cells of glial origin including: astrocytomas and ependymoma.
- Primitive neuroectodermal tumor (PNET) including medulloblastoma and supratentorial
PNET
- Germ cell tumors including: germinoma .
- Other brain tumors are classified in miscellaneous group due to different cells of origin this
group includes: craniopharyngioma, meningioma, hemangiopericytoma, hemangioblastoma
and choroid plexus tumors (Paulino, 2011).
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Figure (3): Classification of pediatric brain tumors according to cell of origin with 4 main
subtypes: gliomas, PNET, germ cell tumors and miscellaneous (Paulino, 2011).
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Table (4): Classification of pediatric brain tumors according to cell of origin (Paulino, 2011).
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1.4.2 CBRTUS distribution statistics of pediatric brain tumors:
The Central Brain Tumor Registry of the United States (CBTRUS) is the most
comprehensive data bank in the united states of all the primary brain and central nervous
system (CNS) tumors (http://www.cbtrus.org/, 2013).
The distribution of brain tumors according to CBRTUS in children aged 0-19 show the
highest percentage of pediatric brain tumors in the frontal, parietal, temporal, and occipital
brain lobes representing 16.9% of childhood tumors. Figure 4 shows the distribution of
childhood tumors by site. Unlike the adults counterparts, the most common pediatric brain
tumor is pilocytic astrocytoma followed by medulloblastoma (Morales & Gaskill-Shipley,
2010).
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Figure (4): Distribution of childhood brain tumors according to CBRTUS by histology is
shown in figure 4. (a) Represents the age group 0-14 and (b) represents the age group 14-19.
http://www.cbtrus.org/

1.4.3 Genetic and non-genetic factors associated with childhood brain tumors:
Exposure to ionizing radiation and presence of familial genetic syndromes correlated with the
development of childhood brain tumors (Fleming & Chi, 2012; Paulino, 2011). Exposure to
ionizing radiation during radiotherapy on the central nervous system (CNS) predisposes to
secondary meningioma and malignant glioma. Familial genetic syndromes represent around
5% of all childhood brain tumors. Examples of familial genetic syndromes are:
Neurofibromatosis Type 1 (NF1) which involves neurofibromin gene mutation on
chromosome 17 resulting in mostly, optic pathway glioma.
Neurofibromatosis Type 2 (NF2) which is presented later in life than NF1 and is caused by
a mutation on chromosome 22 for a gene responsible for Merlin protein transcription and
resulting in acoustic neuroma.
Tuberous Sclerosis (TS) which is mainly associated with subependymal giant cell
astrocytoma ependymoma and glioblastoma and was found to be linked to two genes TSC1
on chromosome 9 and TSC2 on chromosome 16.
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Familial Cancer Predisposition Syndromes which involves mutation on tumor suppressor
gene (TP53) on chromosome17 and increases the risk of several solid tumors including
astrocytoma, glioblastoma and choroid plexus carcinoma.
Von Hippel Lindau which is caused by mutation on the VHL gene on chromosome 3 and is
associated with Cerebellar hemangioblastoma pancreatic and kidney carcinoma.
Other hereditary syndromes include Gorlin’s syndrome and Turcot’s syndrome. It is of great
importance for paediatricians who care for children of familial genetic syndrome to keep a
close follow up and to thoroughly investigate all symptoms.

1.4.4 Grading of childhood brain tumors:

Grading of childhood brain tumors based on the biological behavior of the neoplasm is a
complicated procedure. It takes into consideration its proliferative power, nuclear changes,
mitotic activity, invasiveness and necrosis (Louis, et al., 2007; Patel & Tse, 2004), based on
which the choice of adjuvant therapy is done. The WHO sets a grading scale from (I) to (IV)
where (I) being benign and (IV) being the most malignant. The WHO classification Grade I
describes neoplasm of low proliferative activity and good prognosis, Grade II designates low
proliferative infiltrative neoplasm, Grade III is for lesions which show malignant evidence
and grade IV for malignant neoplasm with high mitotic activity (Louis, et al., 2007).

1.4.5 Diagnosis and treatment:

The new modalities used in brain tumors diagnosis are the computed tomography (CT) and
magnetic resonance imaging (MRI). These modalities improved the accuracy of diagnosis
compared to older modalities such as cerebral angiograms and pneumoencephalograms (Patel
& Tse, 2004). The MRI using gadolinium is used in both initial diagnosis and postoperative
assessment which is done usually 2 days post-surgical resection. MRI is able to detect the
spread of tumor. Staging in brain tumors is not a common practice and mainly depends on
tumor size and the location of the specimen taken, marginal specimen usually show
invasiveness and proliferation while core specimen commonly shows necrosis. (Patel & Tse,
2004; Paulino, 2011).
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Treatment of brain tumor like every other solid tumor involves 3 therapeutic approaches; the
first step is surgical resection. Even though complete resection is one of the few indicators of
good prognosis, the surgeon still has to weigh between complete excision and trying to avoid
any insult to the brain and possible neurological loss. The second step is usually radiotherapy.
This step is the foundation of treatment of pediatric brain tumors. However, risks of
developing secondary brain tumors and /or brain injury resulting in growth impairment as a
result of exposure to ionizing radiation are still present. Lastly chemotherapy can be both
administrated prior to resection to minimize tumor size or after excision to ensure elimination
of cancerous cells.
The treatment protocol is determined by a team of surgeons, oncologists and neurologists
who take into consideration the type of the tumor, the stage and the adverse effect of the
treatment approach. The future promises genetic and molecular targeting therapies with the
increasing

knowledge

of

the

different

molecular

pathways.

Ras/Raf/MAPK,

PI3K/AKT/mTOR and sonic hedghog are three of the potential promising pathways (Packer,
2012).

1.5 Choroid plexus:
Choroid plexus are non-neuronal epithelial cells located in the ventricular part of the
vertebral brain. The choroid plexus together with other cells such as the tanycytes of
circurmventricular organs constitute the brain-CSF-Blood barrier. The main role of the
choroid plexus is cerebrospinal fluid (CSF) production through their access to the leaky
vessels blood compartments. CSF provides the brain and the spinal cord with many
components that are required for normal nervous system function. In addition, it protects the
nervous system from toxins (Wolburg & Paulus, 2010).
Anatomically, the choroid plexus is composed of 4 parts; two of the choroid plexus are
located in the lateral ventricles originating from the inner ventricular system forming an
undulated leaf like structure. The third choroid plexus protrudes from the 3rd ventricle
Finally, the 4th plexus is arises from caudal ventral part of the cerebellum (Strazielle &
Ghersi-Egea, 2000).

28

1.5.1 Choroid plexus tumors:

Choroid plexus tumors are rare neoplasms of the central nervous system. Although, they have
glial origin they are classified separately from gliomas possibly due to their appearance
which is characterized by papillary inter-ventricular growth. Fifty percent of CPT occur in the
lateral ventricles, forty percent in the fourth ventricle and ten percent in the third ventricle or
involve multiple ventricles (Gopal, Parker, Debski, & Parker, 2008; Wolburg & Paulus,
2010).
CPT accounts for 1% to 4% of all childhood brain tumors (Gopal, et al., 2008). They are
more common in pediatric patients than in adults (Rickert & Paulus, 2001). Additionally,
around 10% of CPT are choroid plexus carcinomas (Wolburg & Paulus, 2010).
Choroid plexus tumors are basically classified into three major groups: choroid plexus
papilloma (CPP) which is according to the world health organization (WHO) is a grade I
tumor. CPP represents 80 to 90% of CPTs, they show good prognosis with gross surgical
resection. The atypical choroid plexus papilloma (ACPP) and choroid plexus carcinoma
(CPC) represent a smaller percentage of the CPT than CPP (Gopal, et al., 2008; Wolburg &
Paulus, 2010). CPCs is an aggressive malignant tumor (WHO grade III) represents around
10-20% of CPTs within the age group of 26 to 32 months old (Gopal, et al., 2008). CPCs
have dismal prognosis which necessitate adjuvant treatment approaches. The tumor mainly
involves the lateral and fourth ventricles (Kamaly-Asl, Shams, & Taylor, 2006). CPC is
distinguished from CPP through their increased mitotic figures, nuclear to cytoplasm ratio
and presence of necrosis (Hasselblatt, et al., 2006). All CPTs express vimentin, cytokeratin.
Gene expression profiles identified more than 50 genes with different expression pattern
found in CPC that distinguish it from CPP and ACPP (Hasselblatt, et al., 2006; Louis DN,
2007).

CPC is presented by increased intracranial pressure due to obstruction and overproduction of
CSF. This results in many symptoms which include hydrocephalus, seizures, vomiting,
headache, bulging fontanels and visual disturbance (Gopal, et al., 2008).
In order to improve patients’ prognosis, complete gross resection of the tumor is necessary.
Unfortunately, total resection is linked to higher morbidity due to the tendency of the tumor
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to disseminate through the blood. Two thirds of the CPC tumors metastasize through the
CSF. For the meantime, adjuvant chemotherapy and radiotherapy treatments remain
controversial (Gopal, et al., 2008; Wolburg & Paulus, 2010). Recent studies were focused on
using molecular targeting as treatment alternative in choroid plexus carcinoma. One study
investigated targeting the platelet-derived growth factor receptor (PDGFR) beta using
tyrosine kinase inhibitors. The inhibitor revealed attenuation in the proliferative activity of
the tumor (Koos, et al., 2009). Moreover, another study conducted in the same year on the
methylation pattern of the MGMT (O6- methylguanine-DNA methyltransferase) on choroid
plexus carcinoma. The MGMT promoter revealed a methylation signal in 58% of the tumors
investigated, suggesting a promising role for alkylating agents such as temozolomide in
patients’ treatment (Hasselblatt, et al., 2009).

1.5.2 Genetics of CPCs:
Brain tumors, similar to most cancer types could develop for multiple reasons; hereditary,
chemicals, radiation and viruses. One of the most common dysfunctions involved in CPC
formation is related to the tumor suppressor p53, more commonly found in families with LiFraumeni Syndrome (LFS) (Custodio et al., 2011). Recently, it was reported that fifty percent
of the patients with choroid plexus carcinoma tested positive for germ-line TP53 mutations
(Tabori et al., 2010). Furthermore, somatic mutations in TP53 have been identified in CPC
patients (Tabori et al., 2010). Various chromosomal imbalances have been reported in studies
of comparative genomic hybridization of CPTs. The following chromosomal additions and
deletions have been displayed in patients with CPP: +12p; +12q, and +20p; +1, +4q, and
+20q; +4p; +8q and +14q; +7q, +9p, and +21; -22q; -5q; -5p and -18q (Rickert et al., 2002).
Certain imbalances were found to characterize of the type of tumor and the age of the patient
at the time of the clinical presentation (Rickert et al., 2002).

1.6 Protein folding and quality control pathways:

The role of quality control pathways in protecting against misfolded and aberrant proteins has
been under focus due to its relevance to many human cancers and neurodegenerative
diseases. For the purpose of the work described in the thesis, protein folding and quality
control pathways in eukaryotes will be discussed thoroughly. Protein folding is a process by
which a polypeptide chain is converted to a functional three dimensional protein molecule
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(Roman & Gonzalez Flecha, 2014). The process requires the assistance of multiple
chaperons. As any other machinery folding may encounter several obstacles. These problems
result in misfolded proteins (Garcia-Mata, Gao, & Sztul, 2002). Thirty percent of newly
nascent polypeptide ends up being misfolded. Misfolding may be a result of errors in
transcription, translation or due to environmental factors causing thermal, oxidative or
osmotic stress. Such misfolded proteins may be refolded or eliminated using quality control
mechanisms (Garcia-Mata, et al., 2002; Yao, 2010).

1.7 Quality control pathways:

Cell maintains the proteome homeostasis through balancing de novo protein synthesis and
aberrant or misfolded protein degradation. The process of protein transcription and translation
are extensively covered through many studies. On the other hand, protein degradation has not
received the same attention until the beginning of the year 1940 (Lilienbaum, 2013). The
process of protein degradation is governed by three major different yet interconnected
pathways (Lilienbaum, 2013; Yao, 2010):
-

First, the molecular chaperone pathway uses heat shock proteins (HSPs) to help
efficient refolding of misfolded proteins.

-

Second, the Ubiquitin Proteasome System (UPS) which is responsible for eradication
of the majority of damaged, denatured and misfolded proteins.

-Third, the autophagy system which is an alternative pathway for elimination of
abnormal protein aggregates.
The UPS and the autophagy pathways play a key role in energy production during starvation
in addition to their role as quality control machinery.

1.7.1 The ubiquitin proteasome pathway:
The process of intracellular misfolded protein elimination is initiated by covalent attachment
of one ubiquitin (Ub) molecule to a lysine residue on the protein to be degraded (Lilienbaum,
2013). Ubiquitin protein is a conserve 76 amino acid polypeptide which possess 7 lysine
residues for subsequent ubiquitin bonding in a process known as poly ubiquitination
(Hershko & Ciechanover, 1998) The process is activated by the successive activity of three
enzymes : ubiquitin activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin
ligase (E3). The action is done through energy release from ATP (Lilienbaum, 2013).
Depending on the length and positioning of ubiquitin moieties, different cell machinery are
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recruited for degradation. The most abundant form is lysine 48 Ub which act as a signal for
26S proteasome degradation (Kravtsova-Ivantsiv & Ciechanover, 2012). The barrel shaped
26S proteasome has a channel structure through which the polyubiquinated misfolded protein
gets degraded by specific enzymes (Groll & Huber, 2003). On the other hand, lysine 63 Ub
has been recently associated with being a signal for non-proteasomal pathway including
identification by aggresomes and autophagy pathway (Lilienbaum, 2013).

Figure (5): Schematic illustration of the ubiquitin proteasome pathway. The process is
activated by the successive activity of 3 enzymes E1, E2 and E3; the barrel shaped 26S
proteasome has a channel structure through which the polyubiquinated misfolded protein gets
degraded by specific enzymes (Kinayamu, Chen, & Archur, 2005).

1.7.2 Autophagy:

Autophagy is a dynamic catabolic multistep process for elimination of toxic and misfolded
proteins. The process is essential for cell protection against many diseases including cancers,
infectious diseases, neurodegenerative and myodegenerative diseases (Loos, Engelbrecht,
Lockshin, Klionsky, & Zakeri, 2013).
Autophagy is a Greek term which means “self -eating”. The cell recycles cytosolic
components to be able to survive in stress conditions. There are three main types of
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autophagy: macroautophagy, microautophagy, and chaperone mediated autophagy (CMA).
Each type of autophagy has a different function and pathway. The most characteristic is
macroautophagy which will be referred to as autophagy in the remaining part of the literature
(Chen & Klionsky, 2011).

1.7.3 Macroautophagy pathway:

Autophagy is an essential catabolic process necessary to homeostasis inside the cell. It is
mainly upregulated in cases of nutrient starvation, oncogene activation, infections and
hypoxia (Rosenfeldt & Ryan, 2011). The process starts by formation of a crescent shaped
sequestering double membrane compartment containing cell materials to be degraded, known
as phagophore. The phagophore then elongates into autophagosome which subsequently
fuses with the lysosome forming an autolysosome structure for subsequent degradation
(Klionsky, et al., 2008).

Figure (6): Schematic illustration of the macroautophagy pathway. The process starts by
phagophore formation followed by elongation into autophagosome. The autophagosome then
fuses with the lysosome releasing hydrolases for protein degradation (Grasso, Ropolo, &
Vaccaro, 2015).

The machinery of autophagy is operated by a number of compounds which facilitate the
fusion of the autophagosome with the lysosomes forming the autolysosmes, where toxic
proteins are degraded. The process is initiated by the nucleation of the phagophore with the
help of the autophagy effector activity of LC3; the phagophore is then assembled in a
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phagophore assembly site (PAS). This assembly is done under the control of class III
phosphatidylinositol 3-kinases (PI3K) (Lilienbaum, 2013; Mizushima, Yoshimori, &
Ohsumi, 2011). The phagophore is later expanded in an elongation step forming the mature
autophagosome. Two ubiquitin like (Ubl) complexes involved in the process; the Atg12-Atg5
ubiquitin-like conjugation system and the Atg8 proteins (Johansen & Lamark, 2011). The
mammalian ortholog of Atg8 are the LC3 variants: LC3A, LC3B, LC3C, GABARAP (γAminoButyrate acid receptor-associated protein), GABARAPL1 (GABARAP-Like protein)
(Lilienbaum, 2013). At this step LC3-I is cleaved then lipidated to the LC3-II isoform, which
is then, incorporated into the autophagosome. The LC3-II is one of the specific markers for
autophagy (Chen & Klionsky, 2011). The autophagosome then fuses with lysosome forming
autolysosome in the maturation step for subsequent degradation by specific hydrolases, The
autophagic process is highly regulated machinery and its miss-regulation is linked to many
diseases including cancers (Lilienbaum, 2013).

1.7.4 Diseases associated with impaired autophagy:
Genetic connection between autophagy and cancer has been reported in several studies.
Tumor suppressor genes were found to activate autophagy. On the other hand, oncogenes
were linked to autophagy inhibition (Todde, Veenhuis, & van der Klei, 2009). In addition to
their ambiguous role in cancers, perturbed autophagy was found to contribute to various
diseases including neurodegenerative, cardiovascular and inflammatory diseases. Many
autophagy genes were found inactivated in human cancers (Klionsky, et al., 2008; Rosenfeldt
& Ryan, 2011; Sarkar, et al., 2013).
The autopahgy related gene, ATG Beclin1 hemizygosity was detected in a high percentage in
human breast, ovarian and prostate cancers. Alternatively, the ectopic gene transfer was
found to inhibit tumor growth in mouse and human xenograft models (Levine & Kroemer,
2008; Rosenfeldt & Ryan, 2011; Todde, et al., 2009). UV radiation resistance-associated
gene protein (UVRAG ), ATG5 and ATG12 mutations were reported in colon and gastric
cancer .The p62/SQSTM1 was found overly expressed in breast and lung cancer (Schmukler,
Kloog, & Pinkas-Kramarski, 2014).

1.7.5 The role of LC3 in autophagy:
The microtubule-associated protein light chain 3 (LC3) is the mammalian homologue of yeast
ATG8 that was first detected to localize to autophagosome in the year 2000 by Kabeya et al
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using electron microscopy (Kabeya, et al., 2000). LC3 and LC3 tagged with GFP are the
markers of choice to monitor the autophagic process either by Western blot,
immunofluorescence or life imaging (Klionsky, et al., 2008).
The process of LC3 lipidation begins with the endopeptidaseATG4 which cleaves the LC3
exposing Carboxyl terminal glycine forming the LC3I. An E1-like enzyme (ATG 7) then
activates the LC3I. Next, with the help of a second E2-like enzyme (ATG3) the conjugation
of phosphatidylethanolamine (PE) moiety is catalyzed forming the lapidated LC3II (lc3-PE)
(Chen & Klionsky, 2011; Tanida, Ueno, & Kominami, 2004).

1.7.6 LC3 gene and methylation:
The process of autophagy requires LC3 in the process of nucleation and elongation of
phagophore. A recent study in 2012 (Bai, Inoue, Kawano, & Inazawa, 2012) classified
human LC3 gene family into five members: LC3A variant1:V1, LC3A variant 2, LC3B,
LC3B2 and LC3C.
LC3A-V1 and V2 differ in their transcriptional start site and their N-terminal amino acid
sequence. On the other hand LC3B1 and LC3B2 has different locus and differ in only 1
amino acid. LC3B was always considered as the key player in autophagy. In the former
study, they were able to prove that LC3B and LC3A-V1 play a major role in autophagy.
Another interesting finding was the LC3A-V1 may have a tumor suppressive activity.
Therefore, its inhibition may lead to carcinogenesis. Perturbations in autophagy genes on the
genetic and epigenetic level were found to trigger cancer development. Epigenetic LC3A- V1
inactivation by DNA methylation was detected in many cancer cell lines. Restoration of
LC3A-V1 protein by stable re-expression was found to inhibit tumor growth in vivo in
oesophageal squamous cell carcinoma (ESCC) cell lines (Bai, Inoue, Kawano, & Inazawa,
2012).
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Figure (7): Human LC3 genes exon-intron structure, the diagram shows two variants for
LC3A gene with 2 different transcriptional start sites (Bai, Inoue, Kawano, & Inazawa,
2012).

Cell lines with LC3Av1 silencing: 45.5% of all cell lines had LC3Av1 silenced while they
all showed LC3B expression.

Table (5): Different cancer cell lines and the percentage of LC3Av1 silencing (Bai, Inoue,
Kawano, & Inazawa, 2012).
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1.8 Aggresome and autophagy:

Aggresomes are juxtanuclear protein aggregates which act as storage bins for misfolded
proteins. They are localized in the microtubule organizing center (MTOC). Proteins
sequestered in aggresomes are mainly cleared by autopagy (Yao, 2010).
The aggresomes were first identified by kopito lab in the year 2000. However, their exact
composition is still not completely identified. Ubiquitin, Hsps 27, 70 and 90 and HDAC6 are
key components in the aggresome structure (Richter-Landsberg & Leyk, 2013; Yao, 2010).

1.8 .1 Aggresome pathway:
When nascent polypeptide gets misfolded either due to failure in refolding or a dysfunction in
the proteasome pathway, they aggregate to form aggresomal particles. These particles travel
quickly towards the (MTOC) where they form the aggresome (1-3um) (Garcia-Mata, et al.,
2002). This active process requires dynein/dynactin motor complex transport function and
histone deactylase 6 (HDAC6) associations (Garcia-Mata, Bebok, Sorscher, & Sztul, 1999;
Yao, 2010). The process is accompanied by reorganization of intermediate filament (IF)
cytoskeleton protein vimentin forming a peri-centeriolar cage around the aggresome (GarciaMata, et al., 2002). Accumulation of toxic proteins in aggresome facilitates their degradation
through autophagy (Lee, Shin, Choi, Lee, & Lee, 2002). This rescue machinery protects the
cell from undesirable misfolded proteins and help in cell survival.
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Figure (8): The aggresome pathway: misfolded proteins that don’t get eliminated by the
proteasomal system are transported by the help of HDAC6 and dynein motor to the MTOC
region to be eliminated by autophagy (Rodriguez-Gonzalez, Lin, keda, Simms-Waldrip, et
al., 2008).

Abnormal accumulation of poly-ubiquitinated misfolded protein aggregates has been reported
in a number of neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s
disease (PD), Huntington’s disease (HD), Lewybody dementia and amyotrophic lateral
sclerosis (ALS) (Takalo, Salminen, Soininen, Hiltunen, & Haapasalo, 2013).
In Alzheimer’s disease (AD) 2 different types of aggregates are reported: β amyloid peptide
plaques found extracellular and the intracellular hyperphosphorylated tau proteins (Glenner &
Wong, 1984; Kosik, Joachim, & Selkoe, 1986). In Parkinson disease (PD), accumulation of
intracellular aggregates of synuclein in Lewy bodies is a common feature (Spillantini, et al.,
1997). In Huntington’s disease (HD) aggregates of polyglutamine (Poly-Q) extension
containing Huntington protein are characteristic for the disease (DiFiglia, et al., 1997). Super
oxide dismutase (SOD) aggregates in amyotrophic lateral sclerosis (ALS) are found in motor
neurons (Bruijn, et al., 1998).
Inclusion body formation is a healthy mechanism for cell protection, however when their
accumulation exceeds ability of quality control pathways to degrade the misfolded proteins
they may target different compartments depending on their ubiquitination status and
solubility. In Addition to the aggresome as compartment for insoluble ubiquitinated proteins,
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they transport the misfolded protein for clearance by autophagy at the MTOC. Two different
types of compartments where reported as targets for aggregated proteins:
-The Juxtanuclear quality control (JUNQ) which is a destination for soluble ubiquinated
misfolded proteins. The aggregated proteins are either refolded or degraded using
proteasome. The JUNQ is located in close proximity to the nucleus (Kaganovich, Kopito, &
Frydman, 2008).
The insoluble protein deposit (IPOD) is non-membrane bound. The IPOD recruits the
autophagy machinery for the disposal of insoluble non ubiquitinated aggregates such as in
Huntington disease polyQ Huntington protein and prions (Kaganovich, et al., 2008).
Compartmentalization of inclusion bodies and misfolded protein decrease their toxicity,
improve their refolding through chaperon aid and boost the clearance process by proteasome
or autophagy preventing their cross reaction with other active proteins.

1.9 Cross talk between UPS and autophagy

The aggresome/autophagy and the UPS pathways were long thought to be independent.
Recent studies have shown several areas of crosstalk and complementation between both
pathways in order to maintain homeostasis inside the cell. First level of interaction depends
on the nature of protein to be degraded. Most short lived proteins favor degradation through
the UPS system. Alternatively, long lived proteins and in case of proteasome overloading,
misfolded proteins tend to form aggresomes as substrate for autophagy (Lilienbaum, 2013).
Second level of cross talk identifies the ubiquitin tagging of the protein. The K48Ub tag
favors degradation by 26S proteasome (Kravtsova-Ivantsiv & Ciechanover, 2012), while
K63Ub is a substrate for aggresome autophagy pathway (Tan, et al., 2008).
Third level of interfacing is the adaptor molecules which get attached to ubiquitnated proteins
such as p62/sequestome-1 (SQSTM1) and BRCA1 (NBR) both of which have higher affinity
to the K63 chains thus, they help in recruiting autophagic and not the proteasomal machinery
(Kirkin, Lamark, Johansen, & Dikic, 2009). Another key molecule is HDAC6 which has a
ubiquitin binding domain at its C- terminal and plays a role in aggresomes formation and
transferring both the autophagosomes and lysosomes to the MTOC. Perturbation in UPS was
found to redirect ubiquitinated protein aggregates into aggresome formation and hence
elimination by autophagy (Driscoll & Chowdhury, 2012). Synergetic inhibition of both
proteasomal and autophagy pathways is currently under investigation as powerful anticancer
therapy.
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1.10 HDAC6 and inhibitors:
Histone deacetylases (HDACs) are a group of enzymes that deactylate histones lysine
residues as opposed to the action of histone acetyl transferases (HATs). Histones acetylation
and deactylation play a role in chromatin dynamics and regulation of gene expression
(Simoes-Pires, et al., 2013). However, more than 50 non histone substrates have been
identified as HDACs targets (Fischer, Sananbenesi, Mungenast, & Tsai, 2010). HDACs are
classified into four main classes based on yeast HDAC homology. Class I, II and IV activity
includes Zn dependent mechanism, while class II is a NAD+ dependent mechanism. Class I
has four isoforms (HDAC1, 2, 3 and 8), class III has 7 isoforms while class I has only
HDAC11 isoform. Class II has 2 subclasses and 6 isoforms from which HDAC6 is in class
IIb (Yang, Zhang, Zhang, Zhang, & Xu, 2013). The class HDAC6 plays a major role in the
process of elimination of aggresomes (Simoes-Pires, et al., 2013).
HDAC6 is a 1215 amino acid protein structure with 2 catalytic deactylase domains (DD1 and
DD2), the catalytic deactylase domain DD2 was found to play a major role in tubulin
deactylation (Finnin, et al., 1999; Yang, et al., 2013). In addition, a zinc finger UBD was
found at the C-terminal to bind with high affinity to ubiquitinated proteins. A dynein binding
domain (DBM) is also present to facilitate the transport of ubiquitinated proteins along the
microtubules towards the MTOC. HDAC6 recruits an actin remodelling system which helps
in F-actin network assembly. This network assembly controls autophagosome and lysosome
assembly (HDAC6-P62). Recent studies showed that HDAC6-deficient cells are unable to
form large aggresome hence, misfolded protein elimination is impaired (Richter-Landsberg &
Leyk, 2013).
HDACs inhibitors have been considered as novel potent cancer therapies. Unlike HDAC
inhibitors, tubacin doesn’t affect whole histone acetylation or gene expression (RichterLandsberg & Leyk, 2013). Instead, it increases α-tubulin acetylation and inhibits aggresome
formation through its interference with HDAC6 /dynein interaction.

1.11 mTOR pathway, an overview:
The mammalian target of rapamycin (mTOR) is a highly conserved 289 kD a serine–
threonine kinase. It plays a role in regulation of cell growth, proliferation, metabolism and
survival (Abraham, 2001). The mTOR belongs to the phosphatidylinositol kinase-related
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protein kinases family, and its activation was reported in many human cancers. Two distinct
mTOR complexes exist. The mTOR complex1 (mTORC1) composed of mTOR, raptor,
PRAS40 and mLST8/GbL. The mTORC1 plays a role in protein synthesis and cell cycle,
angiogenesis and autophagy. This complex exhibits sensitivity to rapamycin (Kim &
Sabatini, 2004; Zaytseva, Valentino, Gulhati, & Evers, 2012). Second, The mTOR complex 2
(mTORC2) is composed of mTOR, rictor, mSIN1, mLST8/GbL, protor-1 and PRR5. The
mTORC2 function includes cell survival, proliferation and actin cytoskeleton organization.
Phosphatidylinositol3-kinase (PI3K)/Akt pathway/mTOR pathway was found to be
deregulated in various types of cancers (Laplante & Sabatini, 2009; Zaytseva, et al., 2012).
Targeting this pathway is an attractive goal for anticancer therapy.
Growth factors are the main activators of mTOR pathway. Among these growth factors are
epidermal growth factor, and insulin like growth factor. They bind to their respective
receptors such as receptor tyrosine kinase (RTK) eventually, this activates downstream
signals such as PI3K (Engelman, Luo, & Cantley, 2006).
PI3K phosphorylates lipid phosphatidyl inositol 4-5 bisphosphate (PIP2) to the active
phosphatidyl inositol 3, 4, 5, trisphosphate (PIP3) (Frech, et al., 1997). In turn, PIP3 recruits
PH containing domain AKT phosphoinositide-dependent kinase to the cell membrane in
parallel to recruiting 3-phosphoinositidedependent protein kinase 1 (PDK1) which
phosphorylates AKT at threonine 308 (Thr 308) residue (Yap, et al., 2008). Further
phosphorylation of AKT C-terminal serine 473 (ser473) by mTORC2 is mandatory for full
AKT activation (Hennessy, Smith, Ram, Lu, & Mills, 2005). mTORC1 phosphorylates
downstream p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein 1
(4E-BP1). Both targets play a role in translation initiation. In addition, p70s6 Kinase has a
feedback role in PI3K/AKT pathway inhibition (Zaytseva, et al., 2012).
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Figure (9): The mTOR pathway showing the activating nodes, AKT, PDK1, PI3K mTORC1
and mTORC2 and the negative feedback regulators PTEN and TSC complex (Dienstman,
Rodon, Serra, & Tabernero, 2014).
Rapamycin and its analogs target mTOR inhibition through forming a complex with FKBP12 which inhibits mTORC1 but not mTORC2 (Liu, Thoreen, Wang, Sabatini, & Gray, 2009).
The drawback with rapamycin and its analogues that the S6K-mediated negative feedback
loop is blocked by mtorc1 inhibition, leading to hyperactivation of PI3K signalling which in
turn increases the phosphorylation of Akt -Ser473 and upregulates mTORC2 leading to
further activation of AKT (Efeyan & Sabatini, 2010).
This limitation of rapamycin and its analogues lead to emergence of second generation
mTORC1-mTORC2 dual inhibitors also known as ATP-competitive mTOR kinase inhibitors
such as pp242, AZD, torin 1 and 2. Those inhibitors are able to block PI3K/Akt feedback
signalling (Zaytseva, et al., 2012). In autophagy, the initial sequestration process is regulated
by autophagy-related gene (Atg) products and mTOR proteins. mTOR pathway is activated
by nutrients and growth factors which interacts with the cell membrane, starvation and lack
of sufficient nutrients lead to mTOR

inhibition and further activation of autophagy

(Strimpakos, Karapanagiotou, Saif, & Syrigos, 2009).
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Nutrients which enter the cell by passive diffusion activate mTORC1 through either direct
interaction with mTORC1 or inhibition of tuberous sclerosis complex 1/2 (TSC1/2).
Furthermore, low adenosine 5-triphosphate (ATP) production caused by energy deprivation
causes activation of AMP dependent kinase (AMPK) deriving TSC1/2 activation hence,
mTORC1 inhibition (Gao, et al., 2002).
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2-MATERIALS AND METHODS

2.1-Specimen Collection:

Tumors diagnosis was carried out at the Department of Pathology, Children's Cancer Hospital
Egypt 57357. Patients under 18 years of age diagnosed with choroid plexus carcinoma,
papilloma or atypical choroid plexus papilloma with no prior exposure to radiotherapy or
chemotherapy treatment were enrolled in the study. The study protocol was approved by the
Children's Cancer Hospital Institutional Review Board (IRB). Informed consent was obtained
from the patients or care-givers for the analysis of the stored samples (tissue) in this proposed
study. Standard histological H&E preparations of the tumors were used to establish diagnosis
for choroid plexus carcinoma and papilloma according to the WHO histological criteria.

2.2- Establishment of CCHE-45 Cell Line:

For the generation of the choroid plexus carcinoma cell line, half of the biopsy was paraffin
embedded for histopathology and a small piece was further processed for culturing. For the
generation of CCHE-45 cell line, tumor biopsy was initially minced and then cultured in
RPMI media supplemented with 10% fetal bovine serum (FBS) and 5% antibiotics mixture of
Streptomycin-penicillin-Amphotercin B (Lonza, Maryland, USA) at 37 0C and 5% CO2. Cells
were regarded as immortal and stable after 40 passages, the cell line was established by Dr
Shahenda El-Naggar lab team. CCHE-45 cell line was authenticated using Multiplex Cell
Authentication by Multiplexion (Heidelberg, Germany). The SNP profiles for the cells and
the tumor matched and were unique.

2.3- Karyotype and FISH Analysis:

Metaphase preparations were obtained from cell lines according to standard cytogenetics
procedures. Giemsa staining and clonal chromosomal abnormalities were described according
to the International System for Human Cytogenetic Nomenclature. FISH was performed on
metaphase preparations from the same culture passage as conventional karyotyping. Whole
chromosome paint and TP53/D17Z1 probes were used according to the manufacturer's
instructions (Metasystems, Germany and Abbott, USA). The slides were analysed using
Lieca DM5500 B microscope; subsequently image acquisition using JAI video camera and
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image analyzer system (Applied Imaging Ltd) were used. The former experiments were
conducted by cytogenetics team at Children Cancer Hospital Egypt 57357 under the
supervision of Dr. Sherine Saleem.

2.4- Cell lines, Induction of Autophagy and Drug Treatment:

Neuroblastoma SH-SY5Y and SKNAS cell lines are a kind gift from Dr. Juma Mora at Sant
Joan De Deu, Barcelona. Cells were authenticated using AmpFlSTR® SGM Plus® PCR
Amplification Kit. Cells were grown in RPMI media containing 10% FBS and 1% antibiotics
mixture of Streptomycin-penicillin-Amphotercin B (Lonza, Maryland, USA) at 37 0C and 5%
CO2. For induction of autophagy cells were serum starved in Hank's balanced salt solution
(HBSS, Lonza, Maryland, USA) for 2 and 6 hours. For HDAC6 inhibition cells were treated
with 15 μM tubacin or nil-tubacin (Enzo Life Sciences, New York, USA). For 5-AZA-dC
treatment, cells were treated with either DMSO or 10 mM for 4 successive days (Sigma
Aldrich, St Louis, Missouri, USA).

2.5- Western Blot Analysis:

Whole-cell lysates from both CCHE-45 and SH-SY5Y cell lines were prepared using RIPA
lysis buffer (G-Biosciences, Missouri, USA) supplemented with protease and phosphatase
inhibitors (ThermoScientific, Rockford, Illinois, USA). For Soluble and insoluble fraction
protein isolation, cells were collected from 35 mm dishes and were lysed on ice for 30 min
using 0.1% Triton X- PBS plus protease inhibitors (ThermoScientific, Rockford, Illinois,
USA). Total cell extracts were centrifuged submitted 30 minute at 16,000 g to separate
soluble (supernatant) and insoluble (pellet) fractions. The insoluble fraction was then
resuspended in 1% SDS solution in 1X PBS. The proteins concentration was determined
using Coomassie protein assay (Thermoscientific, Rockford, Illinois, USA). Protein lysate
was resolved by SDS–PAGE (Bio-Rad, Berkely, California, USA) and blotted onto a PVDF
membrane. After blocking with 5% non-fat dry milk in TBST for 1 hour, the membrane was
incubated with primary antibody overnight at 4 0C.
The following primary antibodies were used with (1:1000) dilutions: rabbit anti-LC3A,
rabbit anti-LC3B, mouse HDAC1, mouse ubiquitin, mouse anti-vimentin , mouse anti βActin (Cell Signalling Technology, Danvers, Massachusetts, USA) and mouse anti-acetylated
alpha tubulin (Santa-Cruz Biotechnology, Santa Cruz, California, USA). The membrane was
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washed 3 times with TBS each for 15 mins followed by secondary anti-mouse (1/5000) or
anti-rabbit (1/5000) antibody for 1 hour. The membrane was then washed with TBS 3 times
for 15 minutes each. Bounded antibodies were visualized using ECL chemiluminescence
Western blot substrate (ThermoScientific Rockford, Illinois, USA).

2.6- Immunostaining and Immunofluorescence:

Automated immunostaining was carried out using Ventana BenchMarkXT platform using
vimentin (Ventana,Tucson, Arizona, USA). The following antibodies were then used;
vimentin, cytokeratin (Abcam, Cambridge, Massachusetts, USA), LC3A (Abgent, San Diego,
California, USA) and LC3B. For immunofluorescence, cells were then fixed with 4%
paraformaldehyde, washed with PBS, permeabilised and blocked in 5% normal goat serum
and 0.2% Tween 20 at room temperature for 1h. Cells were then incubated at 370C with
primary antibody overnight in humidified chamber, the following primary antibodies were
used at the following concentrations rabbit anti-LC3A (1:50), rabbit anti-LC3B (1:50), mouse
anti-vimentin (1:25), rabbit anti-HDAC6 (1:50) and mouse anti-acetylated α-tubulin (1:25).
Cells were then washed with PBS and bound antibodies were visualized using the following
secondary antibodies; Alexa Fluor 555 goat anti-mouse or Alexa Fluor 488 goat anti-rabbit
antibody (1:500) (Cell Signaling Danvers, Massachusetts, USA) at room temperature for
1hour. After three further washes in PBS, cells were then counterstained using 4′, 6diamidinophenylindole (DAPI). Images were acquired using LSM 710 confocal scanning
laser microscope (Carl Zeiss, Thornwood, New York, USA).

2.7- Electron Microscopy:

Cell processing and EM imaging was performed at TEM Cairo University Research Park. In
brief, cells were collected from plates using PBS then fixed with osmium tetroxide and
glutaraldehyde, then dehydrated in different concentrations of alcohol and embedded in the
selected epoxy resin. Microtome sections were then prepared at approximately 500 to 1000
µm of thickness with a Leica Ultracut ultramicrotome UCT (Leica Microsystems, Germany).
Thin sections were stained with tolodin blue (1X). Ultrathin sections were prepared at
approximately 75 to 90 of µm thickness and stained with lead citrate and uranyl acetate.
Sections were examined using JEOL (JEM-1400 TEM) and captured by CCD camera AMT,
optronics camera with 1632 x 1632 pixel format as side mount configuration.
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2.8- Proteasome Activity Assay:

Three cell lines (CCHE-45, SH-SY5Y, SKNAS) were cultured overnight in a black wall
transparent bottom 96 well plate. Cells were cultured at 500,000 cells/100ul/well at 37OC
and 5%CO2. The next day 100 µl of proteosome assay loading solution (Abcam, Cambridge,
Massachusetts, USA) were applied and incubated at 37 OC for 4 hours and read at EX/EM
490/620 nm.

2.9- Cell Viability Assay:

Cells were platted at density 3000 cells/ well on a 96 well plate for 24 hours prior to
treatment. Cells were treated with, tubacin, niltubacin (Life Sciences, New York, USA) or
DMSO. After 48 hours the cells were then treated WST-1 (Clonetech, Mountain View,
California, USA) which measures cell proliferation for 4 hours. Absorbance was measured at
440 nm using a spectrophotometric microplate reader (Sunrise, Tecan, Männedorf,
Switzerland). All experiments were performed at least three times. Error bars represent ±
SEM. The absorbance values were normalized to the control values.

Cell proliferation percentage: average OD drug exposure/average OD control X 100

Drug

Concentration

Tubacin

50, 25, 12.5, 6.25, 3.125, 1.56, 0.781uM

Niltubacin

50, 25, 12.5, 6.25, 3.125, 1.56, 0.781uM

Table (6): Different concentrations used for cell viability assay.

2.10- RNA Isolation, cDNA Synthesis and RT-PCR:

RNA isolation was performed using TRizol Reagent (Invitrogen Life Technologies, Carlsbad,
California, USA) according to manufacturer's instruction manual. After decanting the culture
media from the wells, 1ml of TRIzol reagent was added to each well. This was followed by
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incubation for two min at room temperature. Lysed cells were then collected and transferred
to a chilled microcentrifuge tube on ice. For each 1 mL of TRizol reagent, 0.2 mL of
chloroform was added. Tubes were then vigorously shaked by hand for 15 seconds. This step
was followed by an incubation time of three min on ice. Tubes were centrifuged for 15 min at
12,000 × g/ 4°C. Tubes were then angled at 45° to remove the aqueous phase of the sample
by pipetting the solution while avoiding the interphase and the organic layer. The aqueous
phase was then placed in new tube on ice. 0.5 mL of isopropanol was added to the recovered
supernatant and incubated on ice for 10 min the solution was then centrifuged at 12,000 × g
for 15 min at 4°C. The supernatant was then removed leaving the RNA pellet at the bottom.
To wash the pellet 1 mL of 75% ethanol were used per 1 mL of TRIzol reagent. Tubes were
centrifuged at 7500 × g for 5 min at 4°C to discard the wash. The RNA pellet was left to dry
in air for10 min .The RNA pellet was then dissolved in RNase-free water. To determine RNA
concentration UV spectrophotometer (Beckman Coulter DU ® 700 Series) was used. 2 μl
RNA were diluted to a total of 100 μl of distilled water and measured at λ260 and λ280, the
following formula was used to determine the concentration.
RNA concentration (µg/µl) = [OD260 x (dilution factor) x 40]/1000

cDNA was synthesized using RevertAid First Strand cDNA Synthesis Kit (ThermoScientific,
Rockford, Illinois, USA). The following concentrations were used: 1µl of oligo (dT) 18
primer, 1µg of RNA and 10 µl nuclease-free water. Samples were then briefly centrifuged
and left incubated for 5 min at 65°C. After centrifugation, samples were placed on ice. These
reagents were added in the following order; 4µl 5X Reaction Buffer, 2 µl 10 mM dNTP Mix,
1 µl RiboLock RNase Inhibitor 20 u/µl and 1 µl RevertAid M-MuLV Reverse Transcriptase
(200 u/µl) to a total of 20 µl of volume. The sample was incubated at 42°C for 60 min
followed by increasing the temperature to 70°C for 5 min to stop the reaction. Ten µl of PCR
products were loaded on 2 % agarose gel then stained with ethidium bromide. The gel was
then visualized using Gel Documentation System.
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2.11-Polymerase Chain Reaction:

PCR was carried out using DreamTaq DNA Polymerase Master Mix (ThermoScientific,
Rockford, Illinois, USA) using our designed primers LCA_V1_F, LCA_V1_R, LCA_V2_F,
LCA_V2_R, LC3B_F and LC3B_R described in table 8.

Reaction Component

Concentration

DreamTaq DNA Polymerase Master Mix

25 μL

Forward primer

1 μL

Reverse primer

1 μL

Template DNA

5 μL

Water nuclease-free

18 μL

Total volume

50 µl

Table (7): PCR reaction components.

Primer

Sequence

LC3A-V1 forward

5’-CGTCCTGGACAAGACCAAGT-3’

LC3A-V1 reverse

5’-CTCGTCTTTCTCCTGCTCGT-3’

LC3A-V2 forward

5’-ACTCCTGACTGCATGGAAGC-3’

LC3A-V2 reverse

5’-GTCCACAGCTGCTTTTCCAC-3’

LC3B forward

5’-CGGAGAAGACCTTAAGCAG-3’

LC3B reverse

5’-TGACATGGTCAGGTACAAGGA-3’

Table (8): PCR primers for LC3 genes expression.
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2.12-Bisulfite Sequencing:

2.12.1- Extraction of Genomic DNA:

DNA was extracted from CCHE-45 and SH-SY5Y cell lines using GeneJET Genomic DNA
Purification Kit (ThermoScientific, Rockford, Illinois, USA), according to the manufacturer’s
protocol. Cells at 80% confluence were detached from the culture plate using Trypsin (Lonza,
Walkersville, Maryland,USA). The Cells were then transferred in to a microcentrifuge tube to
be pelleted by centrifugation at 1300 rpm x g for 5 min. To resuspend the cells 200 μl of PBS
buffer were used (Lonza, Walkersville, Maryland, USA). Next, to lyse the cells 200 μl of
lysis solution and 20 μl of Proteinase K solution were added. To obtain a uniform suspension
Cells were pelleted then vortexed. Samples were left incubated at 56°C for 10 min with
occasional vortexing until the cells were lysed completely. 400 μl of 50% ethanol was added
to the lysed cells. The lysates were then transferred to GeneJET Genomic DNA Purification
columns and centrifuged at 6000 xg for 1 min. The GeneJET purification columns were then
placed into a collection tube. 500 μl of wash buffer I was then added and centrifuged for one
min at 8000 xg. This step was followed with wash buffer II and centrifugation for 3 min at
(≥12000 x g) which is the maximum speed. The genomic DNA was then eluted with 50μl of
elution buffer. The elution buffer was added to the center of the GeneJET Genomic DNA
purification column membranes for complete to elution of the genomic DNA. Finally, an
incubation period of 2 min for the samples at room temperature followed by centrifugation
for 1 min at 8000 xg. Isolated genomic DNA was stored at -20°C. The total DNA
concentration was measured using UV spectrophotometer (Beckman Coulter DU ® 700
Series). 2 μl of genomic DNA were diluted to a total of 100 μl of distilled water and
measured at λ260 and λ280. To determine the final concentration in µg/µl the following
formula was then used.

DNA concentration (µg/µl) = [OD260 x (dilution factor) x 50]/1000
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2.12.2- Bisulfite Treatment of DNA:
Two µg of DNA were used for bisulfite DNA modification using EpiTect Bisulfite DNA
conversion kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. The total
number of aliquots of the bisulfite mix was then dissolved in 800 μl RNase-free water. The
aliquots were then vortexed until the bisulfite mix was completely dissolved. The bisulfite
reactions were prepared as follows:

Reaction Component
DNA solution

Concentration

RNase-free water

To a total of 140 μl

Bisulfite Mix

85 μl

DNA Protect Buffer

35 μl

Total volume

140 μl

2ng

Table (9): Bisulfite reaction master mix components.

The bisulfite DNA conversion was performed using the following conditions:
Denaturation at 95°C for 5 min,
Incubation at 60°C for 25 min,
Denaturation at 95°C for 5 min,
Incubation at 60°C for 85 min,
Denaturation at 95°C for 5 min,
Incubation at 60°C for 175 min.
Finally Hold at 4°C.

2.12.3- Cleanup of Bisulfite Converted DNA:

Directly after the bisulfite conversion, the bisulfite reactions were centrifuged briefly, and
then transferred to a new 2 ml microcentrifuge tubes. 550 μl of the freshly prepared buffer BL
containing 10 μg/ml carrier RNA was added to each of the samples. The solutions were
mixed by vortexing and then centrifuged briefly. The whole mixture was then transferred into
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the EpiTect spin columns. Spin columns were then centrifuged at maximum speed (≥12000 x
g) for one min. This was followed by discarding the flow-through. For the washing step, 500
μl Buffer BW was added to the spin columns and centrifuged at the maximum speed of
(≥12000 x g) for one min and the flow-through was again discarded. For desulfonation, 500
μl Buffer BD was added to the spin columns and left incubated for 15 min at room
temperature at (25°C). Centrifugation of the spin columns at maximum speed to discard the
flow-through was done at maximum speed for 1 min. To each spin column 500 μl Buffer BW
was added to the spin columns and centrifuged at for 1 min at maximum speed. The flowthrough was then discarded. The washing step was repeated two times followed by
centrifugation to remove any remaining liquid. Finally, 20 μl of the elution buffer (EB) were
added to the center of each of the spin columns membrane to elute the DNA. The columns
were then centrifuged for 1 min approximately at 15,000 xg.

2.12.4: Bisulfite Sequencing Primer Design:

Bisulfite-treated DNA was amplified using the designed bisulfite sequencing primers.
Primers were designed using Methyl primer express® software v1.0 (Applied BioSystems,
Life Technologies, Carlsbad, California, USA).

Figure (10): Schematic presentation of bisulfite sequencing primers.

Primer

Sequence

LC3A region1 Forward

5’-ATTTTTGGTAGTTTTTTTTTAGG-3’

LC3A region 1 Reverse

5’-ACAATCAAACACAAAATAAAACA-3’

LC3A region 2 Forward 5’-GTTTTATTTTGTGTTTGATTGTG-3’
LC3A region 2 Reverse

5’-TCACAACATTCCTTAAAAAAAA-3’

Table (10): Bisulfite sequencing primers.
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2.12.5: Polymerase Chain Reaction:
As previously described.

2.12.6: Size Selection on Agarose:
Onto 1% agarose gel, 100 μl of sequencing PCR products were loaded followed by staining
with ethidium bromide. The gel was then visualized. GeneJET Gel Extraction Kit (Thermo
Scientific, Rockford, Illinois, USA) was used to extract the PCR product according the
manufacturer's protocol. Using a clean scalpel, the gel containing the DNA fragment was
excised and transferred into a 15 ml tube. The binding buffer was then added with the ratio 1
volume: 1 weight to the gel slices. The mixtures were then incubated at 60°C for another 10
min until the gel was completely dissolved. The dissolved gel solutions were transferred to
the purification columns and centrifuged at max speed for 1 min. The columns were placed
into the same collection tubes and the flow-through was discarded. 600 µl of the wash buffer
were added to the GeneJET purification columns and centrifuged for another 1 min to fully
remove any residual washing buffer. For elution, the GeneJET purification columns were
placed into a new 1.5 ml microcentrifuge tubes and fifty µl of elution buffer were added to
the centre of the column membranes. The tubes were then centrifuged for an additional 1
min and the DNA was kept under -80°c.

2.12.7-Tailing Reaction:
The tailing reaction was carried out using the non-proof reading Taq DNA Polymerase
Recombinant enzyme (ThermoScientific, Rockford, Illinois, USA) as follows: The reaction
mixture was incubated for 2 min at 70 ºC.
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Reaction Component

Concentration

PCR product

20 μl

Taq Buffer with KCl (10X)

5 μl

25 mM MgCl2

3 μl

Taq polymerase

1.25 μl

dATP (10mmol)

1 μl

Water

19.75 μl

Total volume

50 μl

Table (11): Tailing reaction components.

2.12.8-Purification:

Purification was carried out using PCR Purification Kit (ThermoScientific Rockford, Illinois,
USA) according to manufacturer's protocol. To a ratio of 1:1 the tailing reaction was added to
the binding buffer and transferred to the Gene JET purification columns. The columns were
then centrifuged for 1 min .The flow-through was discarded, followed by the addition of 100
μl of Binding Buffer to the Gene JET purification columns and centrifuged for 1 min. The
Gene JET purification columns were then transferred into a new 2 ml microcentrifuge tube.
To elute, 25 μl of the elution buffer were added to the purification column membranes and
followed by a centrifugation for 1 min.

2.12.9- Bisulfite PCR Cloning:

PCR products were cloned using InsTAclone PCR Cloning Kit (ThermoScientific, Rockford,
Illinois, USA). The ligation reactions mixture were set as follows; 3 μl of 5X ligation buffer,
0.17 pmol vector pTZ57R/T, 6 μl of purified PCR, 1 μl T4 DNA Ligase giving a total volume
of 30 μl. The Ligation mixtures were left incubated for 1 hour at room temperature (22°C). EColi JM109 competent cells (TaKaRa, Mountain view, California, USA) were left to thaw on
an ice bath directly before use. 50 μl of thawed cells were mixed gently with 2.5 μl of each
ligation mixture for bacterial transformation and kept on the ice bath for another 30 min.
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Cells were then instantaneously heat shocked for 45 sec at 42 ⁰C and quickly returned to the
ice bath for another 2 min. 500 μl of pre –incubated SOC medium at 37 ⁰C were added to the
competent cells and left incubated while shaking (160-225 rpm) for another 1 hour at 37 ⁰C.
SOC media containing transformed E-Coli were then placed on selective media containing 20
mg/ml X-Gal, 100 mM IPTG and 50 mg/ml ampicillin.

2.12.10- Plasmid Extraction:

Plasmid extraction was carried out using GeneJET Plasmid Miniprep Kit (ThermoScientific,
Rockford, Illinois, USA) according to manufacturer's recommendation. Positive colonies
were used to inoculate 5 ml of LB medium supplemented with the 50 mg/ml ampicillin
antibiotic. Bacterial cultures were incubated while shaking at 200-250 rpm, overnight at
37°C. The cultures were then pelleted by centrifugation at 8000 rpm in a microcentrifuge for
2 min at room temperature. Harvested cells were resuspended in 250 µl of the resuspension
solution. Cells were then transferred to a new microcentrifuge tubes. The lysis solution was
then added to lyse the bacterial cells. The tubes were then inverted for 4-6 times to mix
thoroughly until the solution became viscous and slightly clear. The tubes were then
centrifuged for an additional 5 min to pellet the debris and DNA. The upper supernatants
phase was then transferred to the spin columns by pipetting. Spin columns were centrifuged
for another 1 min and discarded the flow-through. For washing, 500 µl of the wash solution
were pipetted to the GeneJET spin columns and followed by centrifugation for 60 sec. This
wash was repeated two times. Finally, 25 μl of the elution buffer were added to the of the
purification column membranes and centrifuged for 1 min to elute the total plasmid DNA.

2.12.11- Colony PCR Identification:

The DNA was amplified using universal M13/pUC Sequencing Primers (Thermo Scientific,
Rockford, Illinois, USA) using Dream Taq polymerase (Thermo Scientific, Rockford,
Illinois, USA) the total reaction volume was 50 µl:
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Reaction Component

Concentration

DreamTaq DNA Polymerase Master Mix

25 μL

Forward primer

1 μL

Reverse primer

1 μL

Template DNA

5 μL

Water nuclease-free

18 μL

Total volume

50 µl

Table (12): Colony PCR reaction components.

2.12.12- DNA Sequencing:

Sequencing was done in our lab using 3130 DNA Analyzer following the BigDye®
Terminator v1.3 Cycle Sequencing protocol (Applied BioSystems, Life Technologies,
Carlsbad, California, USA). Sequences from ten clones from each sample were then analyzed
using BiQ Analyzer to identify methylated and unmethylated CG dinucleotides.

Reaction Component

Concentration

Terminator ready reaction mix

8ul

Template

Equivalent to 300 ng

Primer

3.2 pmol

H2O

Up to 20ul

Total volume

20ul

Table (13): Sequencing PCR reaction master mix components.

2.13- Cloning and Expression of LC3A Gene in Choroid Plexus Cell Line:

2.13.1- LC3A Amplification:
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RNA and cDNA synthesis was done as mentioned above; LC3A-V1 and LC3A-V2
transcripts were amplified from SH-SY5Y and cells using primers LCA_V1_cDNA_F,
LCA_V1_cDNA_R, LCA_V2_cDNA_F and LCA_V2_cDNA_R.

Primer Name

Sequence

LCA_V1_cDNA-F

5’-AAAAAGAATTCATGCCCTCAGACCGGCC-3’

LCA_V1_cDNA-R

5’-AAAAAGGATCCTCAGAAGCCAAGGTTTCC-3’

LCA_V2_cDNA-F

5’-AAAAAGAATTCATGAAGATGAGATTCTTCAGTT-3’

LCA_V2_cDNA_R 5’-AAAAAGGATCCTCAGAAGCCGAAGGTTTCC-3’

Table (14): LC3A-varient I and LC3A-varient II cloning primers.
50 μl of PCR products were loaded onto 1% agarose gels stained with ethidium bromide. The
gel was visualized using Gel Documentation System. DNA was extracted using GeneJET Gel
Extraction Kit K0691 (Thermo Scientific, Rockford, Illinois, USA) according to
manufacturer's protocol as previously described.

2.13.2: Double Digestion:

Purified PCR product and p-IRES2-AcGFP Plasmid (Clonetech, Mountain View, California,
USA), were double digested with EcoR1 and BamH1 restriction enzymes (ThermoScientific,
Rockford, Illinois, USA) as follow:

Restriction enzymes master mix

Concentration

Water, nuclease free

Up to 20ul

10X Fast Digest buffer

2ul

Plasmid DNA(0.2ug)

Variable

FastDigest EcoR1

1ul

FastDigest BamH1

1ul

Table (15): Restriction master mix.
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The reaction was mixed gently and incubated at 37°C for 5 min. This step was followed by a
purification step using PCR Purification Kit (ThermoScientific, Rockford, Illinois, USA) as
described earlier.

2.13.3: pIRES2-AcGFP Plasmid LC3A Insert Ligation:
The Vector – insert reaction mixture was prepared as follow:
Ligation Reaction Components

Concentration

Linear Vector DNA

20-100ng

Insert DNA

5:1

10X T4 DNA ligase buffer

2ul

T4 DNA ligase

1ul

Water, nuclease free

To 20ul

Table (16): p-IRES2-AcGFP Plasmid LC3A insert ligation mixture.
The reaction was incubated for 10 min at 22°C followed by transformation.

2.13.4-Transformation of Cloned Plasmid:
DH alpha Competent Cells (TaKaRa, Mountain View, California, USA) were thawed on ice
bath just before use. Gently cells were mixed with 5 μl of the ligation mixture for bacterial
transformation. Cells were then kept on ice for 30 min. This step was followed by a heat
shock at 42｡C for 45 sec, cells were then returned to ice for an additional 2 min. 500 µl of
SOC medium pre-incubated at 37｡C were added to the cells and left incubated while shaking
at 225 rpm for 1 hour at 37｡C. cells were then plated on kanamycin selective media. Plasmid
preparation was then performed on selected colonies as previously described using GeneJET
Plasmid Miniprep Kit (ThermoScientific, Rockford, Illinois, USA). Positive colonies were
sequenced to confirm correct sequences for both variants to match LC3A-V1 (NM_032514.3)
and LC3A-V2 (NM_181509.2).
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2.13.5: Lipofectamine Transfection:
CCHE-45 Cells were cultured and left to reach 90% confluency, Lipofectamine 2000 (Life
Technologies, Carlsbad, California, USA) was then diluted in serum free media, mixed with
2.5 ug of DNA (empty vector, LC3A-V1 or LC3A-V2 ) and incubated for 5 min at room
temperature. The DNA-lipid complex was then added to the cells and incubated for 24, 48 or
72 hours.
2.14-BrainSpan Data Analysis:
Human BrainSpan project was used to obtain RPKM for the LC3A (ENSG00000101460) and
LC3B (ENSG00000140941). Expression values were calculated for each gene according to
developmental stage or across different brain regions. Analysis was performed using R
statistical language version 3.2.2.

2.15-Statistical Analysis:
All experiments were repeated three times. Data are expressed as + SEM. The significance of
difference among means was evaluated using paired Test. Significant differences were
defined as p ≤ 0.05.
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3-RESULTS

3-1: Constitutive formation of aggresomes in choroid plexus carcinoma line CCHE-45 is
repressed by HDAC6 inhibitor.

We propagated a primary cell line, named CCHE-45, from a CPC surgical excision sample.
Identity with the original tumor was verified using Multiplex Cell Authentication service
(MCA), which utilizes a single-nucleotide polymorphism (SNP) profiling approach. Cells
were passaged over forty times before considered immortal. Karyotyping was done in the
pathology lab in children cancer hospital 57357.CCHE-45 cells presented with two clones,
one clone was triploid (62~75 chromosomes) and the second clone was hexaploid (137
chromosomes). Structural abnormalities included translocation (2;18)(q32;q23), (1;3)(?;q27)
and (20;22)(p11;q11) and del(17)(p11) (Figure 11 ) in both clones whereas the hexaploid
clone had two copies from each translocation

Figure 11: FISH analysis using red and green probes to detect Tp53 gene and
centromere, translocation t(1;3) and translocation t(2;18).

When immunostained with vimentin, a marker for choroid plexus tumors, CCHE-45 cells
displayed a single perinuclear vimentin positive inclusion in all cells and in different passages
(early and late); however, it varied in their intensity and size (Figure 12).
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Figure 12: Aggresomes subcellular localization was identified by the formation of vimentin
capsules (white arrows) at the MTOC. CCHE-45 cells were cultured under normal condition,
fixed and immunostained with anti-vimentin (green) and visualized using Alexa Flour 488 antirabbit IgG antibody. Cells were counterstained with DAPI (blue) to visualize the nucleus.

The presence of vimentin cage like structures is characteristic of aggresomes and is formed
by the collapse of the intermediate filament. Examination of CCHE-45 cells by transmission
electron microscopy (TEM) further confirmed the presence of dense to light 2-3 µm in
diameter perinuclear structures in most of the examined cells (Figure 13).

Figure 13: TEM examination of CCHE-45 cell line showing aggresomes ultra structures (a=
aggresomes, n= nucleus).
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These inclusion bodies varied in its density and in size. To ensure that the collapse of
vimentin filaments was not a feature of the cell line and it is present in the original tumor, we
examined a cell pellet from CCHE-45 cells and compared it to its original tumor tissue. Both
CCHE-45 cells and the parent tumor displayed similar structures (Figures 14A and 14B).
Unexpectedly, cytokeratin also contributed to the structure of aggresomes (Figures 14A and
14B).

A.

B.
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Figure 14:
A. CCHE-45 cell pellet was FFPE and immuno-stained with cytokeratin and vimentin.
We further examined the pattern of vimentin and cytokeratin expression in CPP and ACPP.
B. CCHE-45 original tumor biopsy obtained at surgical resection was FFPE and immuneBoth tumors displayed a homogenous cytoplasmic pattern for both markers suggesting that
stained withare
cytokeratin
aggresomes
unique to and
CPCvimentin.
(Figure 17C).

We further examined the pattern of vimentin and cytokeratin expression in CPP and ACPP.
Both tumors displayed a homogenous cytoplasmic pattern for both markers suggesting that
aggresomes are unique to CPC (Figure 14C).

Figure 14C: CPP and ACPP H&E preparation and immunohistochemical analysis for
vimentin and cytokeratin.
To exclude any malfunction in the Ubiquitin proteasome System (UPS) in the CCHE45 cell
line proteasome activity was tested. UPS failure may result in accumulation of misfolded
proteins in the form of aggresomes. CCHE-45 was compared with two other cell lines SHSY5Y and SKNAS cell lines, (Figure 15) using proteosome assay loading solution (Abcam), and
measured at EX/EM 490/620.
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Figure 15: Proteasome activity assay comparing CCHE45 with SHSY5Y and SKNAS cell lines
20S activity was measured according to protocol, relative fluorescence intensity was measured
with a plate reader.CCHE45 showed high activity.

Misfolded or aggregated proteins that cannot be eliminated by the proteosome are
concentrated by HDAC6 and transported by the action of the dynein motor protein to the
aggresomes. It has been previously shown that inhibitors of HDAC6 have an antitumor effect
when coupled with conventional therapy. In this context, we evaluated the effect of different
concentration of tubacin and its inactive analog niltubacin on CCHE-45 cells. Significant
reduction in CCHE-45 proliferation was reported in a dose-dependent manner with no change
in niltubacin treated cells (p-value = 0.01) (Figure 16).
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Figure 16: The effect of tubacin and niltubacin on CCHE-45 cell line was evaluated by cell
viability assay. Cells were treated with different concentration of both drugs for 48 hours
before treating with WST-1 for 4 hours; absorbance was then read at 440 nm. Results were
averaged over three separate experiments. Error bars represent ± S.E.M, represent significant
p-value where p ≤ 0.05.

Treatment with tubacin resulted in the increase of acetylated α-tubluin and no change in
vimentin protein levels (Figure 17), supporting the known effect of tubacin as an HDAC6
inhibitor on α-tubulin acetylation.

Figure 17: Immunoblot analysis for CCHE-45 after treatment with DMSO, tubacin
(15µM), niltubacin (15µM) or non-treated (control). β-actin was used as a loading control.
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Furthermore, due to the significant effect of tubacin on CCHE-45 proliferation, we
hypothesized that tubacin treatment will result in disappearance of aggresomes as a
consequence to HDAC6 inhibition. Despite HDAC6 inhibition, aggresomes were detected in
tubacin treated cells however, they presented mainly as hollow cage structures (Figure 18).

Figure 18: Immunofluorescence staining of CCHE-45 cells treated with 15µM of tubacin
for 48 hours. CCHE-45 cells were immunostained with vimentin (green) and counterstained
using DAPI.

3-2:Effect of nutrient deprivation on autophagy markers and aggresome clearence .

The presence of aggresomes has been linked to cellular proteotoxic overload that cannot be
eliminated by the proteasome. Consequently autophagy becomes the main route for
aggresomes clearance. To further address the contribution of autophagy to the observed
phenotype, we treated CCHE-45 cells with HBSS for 2 and 6 hours. The induction of
autophagy was initially monitored by the change in LC3B and LC3A processing. While
LC3B and LC3A protein levels were reduced in the neuroblastoma line SH-SY5Y after
nutrient deprivation for 2 and 6 hours (Figure 19), CCHE-45 cells displayed reduction in
LC3B with no detectable LC3A protein in control cells and no change in vimentin levels
(Figure 19).
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Figure 19: CCHE-45 and SH-SY5Y cells were cultured under normal condition or serum
starved for 2 or 6 hours in HBSS. Whole cell lysates were collected and analyzed by
Western blot analysis. β-actin was used as a loading control.
Due to potential cross-reactivity between available antibodies for both LC3A and LC3B, both
proteins immunoblots were always performed on separate membranes. The reduction in
LC3B levels and the lack of change in vimentin protein levels following nutrient deprivation
suggested no effect on aggresome clearance, accordingly IF was further used to monitor
autophagy in both cell lines. IF for LC3B primarily showed nuclear localization under control
condition and formed cytoplasmic puncta upon nutrient deprivation in CCHE-45 (Figures
20A) confirming autophagy. Furthermore, both LC3B and the lysosomal marker LAMP2 colocalized with each other or with vimentin upon induction of autophagy (Figure 20A).
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Figure 20A: Cells were cultured under normal condition or serum starved in HBSS for 2
hours. CCHE-45 cells were coimmunostained with vimentin and LC3B, vimentin and
LAMP2 or LC3B and LAMP2. Cells were fixed in 4% paraformaldehyde, immunostained
with anti-LC3B, anti-LC3A, anti-vimentin or anti-LAMP2 and visualized using Alexa Fluor
488 goat anti-rabbit antibody or Alexa Fluor 555 goat anti-mouse.

However, upon autophagy induction LC3A co-localized with LC3B either to the aggresomes
or to other cellular sites (Figure 20A). LC3B was primarily nuclear in SH-SY5Y under
normal conditions while LC3A protein was detected in the cytoplasm and the nucleus (Figure
20B). When treated with HBSS for 2 hours, LC3B displayed a cytoplasmic puncta indicative
of autophagy induction while LC3A became entirely cytoplasmic with some co-localization
with LC3B protein. On the other hand LAMP2 co-localized with both LC3A and LC3B
(Figure 20B).
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Figure 20B: SH-SY5Y cells were cultured under normal condition or serum starved in HBSS
for 2 hours. Cells were fixed in 4% paraformaldehyde, immunostained with anti-LC3B, antiLC3A, anti- LC3A and LAMP2 or LC3B and LAMP2. Cells were visualized using Alexa Fluor
488 goat anti-rabbit antibody or Alexa Fluor 555 goat anti-mouse. DAPI was used as
counterstain to visualize the nucleus.
Despite the induction of autophagy, aggresomes were detected in CCHE-45 cells, however
they formed hollow ring like structures similar to tubacin treated cells suggestive of altered
vimentin assembly. TEM for CCHE-45 cells showed autophagic vacuoles present in close
proximity to aggresomes

Figure 20 C: TEM examination CCHE-45 and SH-SY5Y cells using JEOL (JEM-1400 T).
3-3:
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3-3: Silencing of LC3A-V1 expression in choroid plexus carcinoma tumors by intergenic
CpG island methylation

Recent reports have shown that LC3A expression is absent in several tumors and corresponds
to poor prognosis. The absence of LC3A protein in CCHE-45 coupled with previous reports
of epigenetic inactivation of LC3A-V1 in a number of tumors incited us to test for its
silencing in CCHE-45 cells . To verify that the lack of expression of LC3A in CCHE-45 is
not related to the tissue of origin, BrainSpan transcriptome dataset were used to examine the
expression of LC3A and LC3B in normal brain tissues (Figure 21).

Figure 21: LC3A and LC3B gene expression as a function of different developmental
stages (upper panel) and as a function of different regions in the brain (lower panel) using
RNA-Seq data from the BrainSpan Project. Expression of LC3A and LC3B were detected
in all developmental stages and at different part of the brain. pcw = post conception weeks,
mon = month, yrs = years, Ocx = occipital neocortex, M1C-S1C = primary motor-sensory
cortex, AMY = amygdaloid complex, MGE = medial ganglionic somatosensory
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LC3A and LC3B were found to be expressed in all brain regions and during different
developmental stages. LC3A gene has been recently shown to have two transcriptional
variants which differ in transcription start site (Figure 22).

Figure 22: Schematic representation of LC3A exon-intron structure showing the difference
in transcriptional start site between LC3A-V1 and LC3AV-2 (Bai et al, 2012).

Expression of both LC3A variants were absent in CCHE-45 cells, while only LC3A-V1 was
present in SH-SY5Y cells, supporting that variant one is the predominant variant (Figure 23).

Figure 23: Expression of LC3A –V1, V2 and LC3B were examined using RT-PCR in
CCHE-45 and SH-SY5Y cells. β-actin was used as an internal control.
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Furthermore, examining both LC3A and LC3B in the parent tumor tissue supports that
inactivation of the former (Figure 24).

Figure 24: Immunohistochemical analysis for LC3A and LC3B expression in CCHE-45
original tumor. LC3A was detected in normal brain tissue (region a) while tumor area (region
b) was negative for LC3A expression. On the other hand LC3B expression was detected in
normal and tumor tissue region (c and d) respectively.

We further examined the CpG island status of LC3A-V1 CCHE-45 in comparison to SHSY5Y which is previously reported to be methylated in a wide range of tumors including
multiple myeloma cells which are known to form aggresomes. Concordant with this data, is
the fact that
Loss of LC3A-V1 expression in CCHE-45 was due to intergenic CpG island methylation
(Figure 25A). Bisulfite sequencing of CCHE-45 parent tumor indicated complete promoter
methylation in all ten clones examined (Figure 25B).

72

Figure 25A: Bisulfite modified DNA PCR products from CCHE-45 and SH-SY5Y, the
diagrams show methylated CG dinucleotide in CCHE-45 R1 and R2 (closed circles) with no
methylation detected in SH-SY5Y (open circles). Primers were designed to amplify region 1
and region 2 (R1 and R2 respectively) to examine the methylation status of CpG island
upstream of LC3A-V1 using bisulfite sequencing.
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Figure 25B: Bisulfite sequencing for CCHE-45 original tumor. Region 2 was amplified
using R2 primer set. Methylated CG dinucleotide is indicated by closed circles.

Further treatment of CCHE-45 with the general demethylating agent 5-Aza-2-deoxycytidine
(5-AZA-dC) resulted in the re-expression of LC3A (Figure 26), supporting the role of
methylation in the regulation of LC3A-V1 expression.
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Figure 26: Western blot analysis for CCHE-45 cells treated with 10µm 5-AZA-dC for 4
days then serum starved in HBSS for 2 hrs. LC3A protein was restored following 5-AZA-dC
treatment. No change in vimentin expression was detected.

We next examined the expression of both genes in CPTs using immunohistochemical
analysis. While LC3B expression was detected in all tumors, LC3A expression was positive
in CPP and either focal or absent in both ACPP and CPC (Figure 27).

Figure 27: Schematic representation for immunostaining for 19 cases choroid plexus
carcinoma (blue), atypical choroid plexus carcinoma (yellow) or choroid plexus papilloma
(olive) stained with vimentin, LC3A or LC3B. Solid, partial and clear color indicates
positive, focal and negative stain respectively.
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3.4-LC3A re-expression induces aggresome clearance by lysosomal recruitment that is
independent of autophagosome formation.

Because of the correlation between aggresomes and LC3A-V1 silencing, we reasoned that the
lack of expression in CPC may affect aggresomes accumulation. To further elucidate the role
of LC3A, we cloned LC3A-V1 or LC3A-V2 cDNA downstream of a CMV promoter and
transiently transfected CCHE-45 cells with empty vector or LC3A-V1 or LC3A-V2.
Transfection efficiency was monitored by GFP positivity. The expression of LC3A was
further confirmed by immunoblot analysis (Figure 28). A decrease in LC3B was observed in
LC3A-V1 transfected cells (Figure 28).

Figure 28: Western blot analysis for CCHE-45 transfected with p-IRES2-AcGFP empty
vector (EV), p-IRES2-AcGFP-LC3A-V1 (LC3A-V1) or p-IRES2-AcGFP-LC3A-V2 (LC3AV2).

To visualize the effect of LC3A on aggresomes, CCHE-45 cells were immune-stained for
vimentin 48 hours post transfection. Consistent with 5AZA-dC treatment, LC3A displayed a
cytoplasmic filament like appearance (Figure 29). Furthermore, less number of aggresomes
was observed and vimentin displayed a filament like organization or hollow circles rather
than dense localized peri-nuclear inclusions (Figure 29). Furthermore, LC3A mainly
surrounded the aggresomes forming a ring around the inclusion or was in close proximity
with minimal colocalization. LAMP2 co-localized with LC3A and surrounded the
aggresomes as well as detected within the aggresomes (Figure 29).
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Figure 29: Immunofluorescence analysis of CCHE-45 cells transfected with p-IRES2AcGFP empty vector) or p-IRES2-AcGFP-LC3A-V1. Cells were immunostained with LC3A
and LC3B, vimentin and LC3A or LC3A and LAMP2 and visualized using Alexa Fluor 488
goat anti-rabbit antibody or Alexa Fluor 555 goat anti-mouse. The figure shows the
disappearance of aggresomes and the colocalization with LAMP2 in p-IRES2-AcGFPLC3A-V1 transfected cells.
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4-DISCUSSION

Mutations, metabolic challenges and stress conditions are common reasons for the production
of aberrant proteins (Chen, Retzlaff, Roos, & Frydman, et al., 2011). Consequently, cells
exert several quality control strategies aimed at refolding (Hartl, Bracher, & Hayer-Hartl,
2011), degrading or sequestering aberrant protein species (Heck, Cheung, & Hampton, 2010).
Insoluble protein deposit (IPOD) and intranuclear quality control (INQ) are two
compartments for protein sorting and sequestration for cytoplasmic and nuclear proteins,
respectively (Chen, Retzlaff, Roos, & Frydman, et al., 2011, Miller et al., 2005).
Additionally, aggresomes are specialized, cytoplasmic cage-like structures that form at the
microtubule organizing centers (MTOC) to sequester misfolded proteins (Kawaguchi,
Kovacs, McLaurin, Vance, et al., 2003). The role of protein sequestration into inclusion
bodies in cancer is not well defined. Here we report the development of a new choroid plexus
carcinoma cell line CCHE-45. The cells were characterized by the presence of a single cage
like inclusion body at juxtanuclear position that was positive for vimentin. These structures
have been identified previously as aggresomes (Johnston et al., 1998). Recently, the JUxta
Nuclear Quality control compartment (JUNQ) was used to describe vimentin positive
structures that share similar cellular position as aggresomes (Kaganovich, Kopito, &
Frydman, 2008).Furthermore, it was proposed that aggresomes may represent a mature state
of JUNQ (Heck, Cheung, & Hampton, 2010). In the case of CCHE-45 cells, their constitutive
presence in all cells and lack of mobility supports aggresome description rather than JUNQ.
While most reports suggest that aggresomes are formed by single intermediate filaments
(Johnston et al., 1998, Saliba, Munro, Luthert, & Cheetham, 2002), we find that both
cytokeratin and vimentin contribute to the cage like structure of aggresomes in CPC. The
absence of aggresomes in both CPP and ACCP and their presence in CPC supports the notion
that their accumulation is more likely to be associated with aggressive tumors. The formation
of aggresomes was shown to be dependent on the collection of aggregates by HDAC6 and
dynin motor proteins (Kawaguchi, Kovacs, McLaurin, Vance, et al., 2003). The significant
decrease in cell proliferation following treatment with tubacin highlights the role of
aggresomes as a protective mechanism against aberrant proteins. Furthermore, the
disassembly of aggresomes following HDAC6 inhibition with no change in vimentin protein
levels suggests that aggresome assembly is coupled to aggregates transport (Kawaguchi,
Kovacs, McLaurin, Vance, et al., 2003).
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While aggresomes are considered a cytoprotective mechanism, they are ultimately eliminated
by autophagy. Monitoring autophagy has proven to be challenging due to difference in tissue
response to stress as well as limitations associated with different assays (Klionsky, 2016).
LC3B is commonly used as a marker for induction of autophagy (Tanida, Ueno, &
Kominami, et al., 2005); however MAP1LC3/LC3 family members encompass LC3A, LC3B
and LC3C where the former two have been reported to participate in autophagosome
formation (Shpilka, Weidberg, Pietrokovski, & Elazar, 2011, Koukourakis, Kalamida,
Giatromanolaki, Zois, et al., 2015). Examining both LC3A and LC3B following nutrient
deprivation, we find that both proteins are present and processed to form cytoplasmic puncta
indicative of autophagy activation in SH-SY5Y cells. In contrast, LC3B presented with both
bands (LC3B-I and LC3B-II) under normal growth condition and no detectable LC3A protein
in CCHE-45 cells. The increased signal for autophagosome detected by the presence of
lipdiated form of LC3B and the cytoplasmic puncta for LC3B supports the activation of
autophagy at a basal level in CCHE-45 cells. At the same time, the decrease in LC3B-I and
LC3B-II protein levels following nutrient deprivation supports the notion of enhanced
autophagy flux in CCHE-45 cells. Based on these results we propose that CCHE-45 cells
exhibit enhanced autophagy flux to overcome proteotoxic stress. Furthermore, the
disassembly of the vimentin cage following autophagy induction supports the role of induced
autophagy as a regulator of aggresomes. By inducing non-selective macroautophagy aberrant
proteins are removed which in turn results in altered assembly of the vimentin cage rather
than removal of aggresomes by engulfment. This notion is further supported by TEM for
CCHE-45 cells showing autophagic vacuoles present in close proximity to aggresomes. This
is in line with previous reports for autophagic vacuoles and lysosome recruitment to
aggresomes to facilitate its degradation following proteasome inhibition (Zaarur, Meriin,
Bejarano, Xu, et al., 2014).
Deregulation of signalling pathways and microtubule associated proteins which have been
shown to correlate with the clinical outcomes in some tumors. For instance LC3B-II down
regulation correlated with poor survival in GBM (Huang, Bai, Chen, Li, & Lu, 2010) and the
loss of LC3A expression by promoter-silencing was found in different tumor cell lines (Bai,
Inoue, Kawano, & Inazawa, 2012). Furthermore, both LC3A and LC3B were found to form
stone like structures which correlated with poor prognosis (El-Mashed, O’Donovan, Kay,
Abdallah, Cathcart, & O’Sullivan, et al.,2015). Analysis of BrainSpan RNA-Seq data
identifies LC3A and LC3B to be ubiquitously expressed in the brain during different
developmental stages. While LC3B is expressed in CCHE-45 cells, LC3A-V1 was silenced by
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promoter methylation in CCHE-45 and primary CPC supporting previous reports of LC3A-V1
inactivation. Interestingly, multiple myeloma, which is known to form aggresomes, shows
inactivation of LC3A-V1 by the same mechanism. These results support a potential
correlation between LC3A-V1 gene silencing and the development of aggresomes. The
disassembly of the vimentin cage following LC3A-V1 expression coupled with recruitment
of LAMP2 independent of LC3B suggestive of autophagy activation independent of
macroautophagy. These results support the hypothesis that under the stress imposed by
protein overload, LC3A modulates cellular basal quality control.
In conclusion, protein misfolding and aggregation has been mainly investigated in
neurological disorders. In cancer, understanding cellular response to aberrant protein which is
a common feature to cancer cells has been primarily investigated using ectopic expression of
aberrant proteins coupled with proteasome inhibitors. CCHE-45 cells provide a new model
for understanding aggresome dynamics without disruption of tumor environment. Moreover,
it serves as a new model to investigate how cancer cells employ autophagy quality-control to
achieve proteostasis highlighting a new role for LC3A protein. Finally our work identifies
aggresomes as a potential new molecular target for CPC and other tumors with a similar
phenotype.
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5-FUTURE DIRECTION

In our research we were mainly investigating the vimentin cage forming the aggresomal
structure; our next step is to study the expression of the intermediate filament cytokeratin.
Cytokeratin was found to contribute to the structure of aggresomes formation in our cell line
and the original tumor. As with the vimentin expression we will study the effect of HDAC6
inhibitor on cell proliferation. Autophagy activation by nutrient deprivation and how would it
affect the cytokeratin structure and concentration would be further studied. We will also
study the effect of treatment with a demethylating agent such as 5-Aza-dC and transfection
with LC3A gene on the structure of the cytokeratin and compare it with the effect on the
vimentin cage. In addition, we need to further study the different component contributing in
the aggresome structure other than vimentin and cytokeratin.
In this thesis study we were mainly concerned about the mechanisms contributing to
clearance of the aggresomes such as the ubiquitin proteasomal pathway and autophagy. Our
next aim is to tackle the mechanisms that lead to its formation in the first place. The different
stresses that lead to protein misfolding and the reason they ended up contained by
aggresomes from their ubiquitination status to solubility will be further investigated.
A recent study showed an asymmetric segregation of aggresomes during mitosis, we plan to
study the fate of aggresomes during cell division in CCHE-45, using different molecular
biology techniques and many cytological assays. We will investigate whether the cell line
will undergo normal mitosis. The segregation pattern of the aggresomes whether symmetric
or asymmetric will be compared with other cell lines.
At last we would like to target the aggresomes with different potent and selective new
generation inhibitors such as Tubastatin A, we will verify its effect on cell proliferation,
vimentin and cytokeratin expression and aggresomal clearance. Ultimately, we hope to able
to find a potential target in choroid plexus carcinoma that can be used for future treatment.
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